Betnovate

Betnovate is a widely prescribed topical corticosteroid available as a cream, ointment, and scalp application, manufactured by GlaxoSmithKline. It contains betamethasone valerate 0.1% as its active ingredient and is classified as a potent corticosteroid (Group III in the UK classification system). Betnovate is used to treat a range of inflammatory skin conditions where a potent steroid is required to achieve adequate symptom control, including atopic eczema, contact dermatitis, discoid eczema, seborrhoeic dermatitis, psoriasis of the body and scalp, and lichen planus.

Why Betnovate Is Effective

Betnovate works by suppressing the inflammatory processes that cause the characteristic redness, itching, scaling, swelling, and discomfort of inflammatory skin diseases. In conditions such as eczema, the immune system mounts an excessive inflammatory response in the skin that damages the skin barrier and causes intense itching. By applying betamethasone directly to the affected area, Betnovate rapidly reduces inflammation locally without the systemic side effects that accompany oral corticosteroids.

Formulation Options

Betnovate is available in three main formulations to suit different skin types and conditions. The cream is a water-in-oil emulsion that is lighter and more cosmetically acceptable than the ointment; it is generally preferred for moist, weeping, or acutely inflamed skin. The ointment is an anhydrous, greasier preparation that provides better occlusion and hydration, making it suitable for dry, lichenified (thickened) skin. The scalp application is an alcoholic lotion formulation designed for use on the hairy scalp, where cream and ointment are impractical to apply. A reduced-strength preparation, Betnovate-RD (betamethasone valerate 0.025%), is also available for milder conditions or as a step-down maintenance formulation.

Important Safety Limits

Betnovate should be used for the shortest duration necessary to bring the skin condition under control. Long-term or widespread use without appropriate medical supervision carries a significant risk of skin thinning, stretch marks, and systemic absorption of corticosteroid. It should not be used on the face, in the skin folds, or on broken or infected skin without medical advice.

How to Apply Betnovate

Apply Betnovate cream or ointment once or twice daily to the affected skin as prescribed. Massage a thin layer gently until absorbed. Use the FTU method to avoid applying too much: one fingertip unit covers approximately two adult palm areas. Wash hands after applying unless the hands are being treated.

Use for the shortest time needed to bring the condition under control. For most acute flares, four to seven days is often sufficient. Once the skin has improved, step down to a less potent steroid for maintenance.

Using Betnovate Scalp Application

Apply to the scalp and massage into affected areas twice daily. The alcoholic formulation dries rapidly. Avoid open flames or naked lights due to the alcohol content. Keep away from the eyes.

The standard dosing schedule for Betnovate is once or twice daily applied as a thin layer to affected skin. Clinical guidelines recommend applying the minimum quantity that produces a satisfactory response.

Fingertip unit (FTU) guidance provides a practical framework for dosing by body area:

• Face and neck: 2.5 FTU
• One arm: 3 FTU
• One hand (both sides): 1 FTU
• Trunk (front or back): 7 FTU
• One leg: 6 FTU
• One foot: 2 FTU

For the scalp application, a few drops sufficient to cover the affected area are applied twice daily.

In children, Betnovate should be used with caution, at the lowest potency suitable for the condition and for the shortest possible time. Betnovate should not routinely be used in children under one year; in children aged 1-17 years, use should be under medical supervision. Elderly patients may have thin, fragile skin and are more susceptible to skin atrophy; shorter treatment courses with careful monitoring are recommended. No specific dose adjustment is required for renal or hepatic impairment with topical use given minimal systemic absorption.

Betnovate is well tolerated in short treatment courses. Side effects become more likely with prolonged or excessive use and are greatest in thin-skinned areas.

Common Side Effects

The following are reported with regular use of Betnovate:

• Skin thinning (atrophy), most prominent over thin-skinned and flexural sites
• Striae (stretch marks), may be permanent, most common in groin and axillae
• Telangiectasia (fine superficial blood vessels becoming visible)
• Easy bruising or fragility of the skin
• Increased hair growth (hypertrichosis) at the application site
• Mild stinging or burning sensation on first application

Serious Side Effects

The following require medical assessment:

• Skin infections: betamethasone suppresses local immunity; bacterial, fungal, and viral infections (including tinea, candida, impetigo, and herpes) can worsen significantly under potent steroid treatment, any sign of infection during treatment requires prompt evaluation
• HPA axis suppression: particularly in children and with extensive body surface area coverage, manifested as unusual fatigue, weight gain, or failure to thrive
• Perioral dermatitis or steroid acne following facial use
• Cushing's syndrome features with large quantities used over prolonged periods
• Glaucoma or raised intraocular pressure if the preparation inadvertently contacts the eyes repeatedly

Restricted Areas and Duration

Betnovate must not be applied to the face without medical supervision. The skin of the face, particularly around the eyes, nose, and mouth, is thin and highly susceptible to steroid-induced atrophy, perioral dermatitis, rosacea-like reactions, and telangiectasia. When facial use is unavoidable and medically supervised, treatment must be kept to the minimum duration (typically five days maximum) and the smallest quantity possible. The eyelid skin is particularly at risk of causing elevated intraocular pressure if steroid preparations are used in or around the eyes.

Betnovate should not routinely be used on the genitals, armpits, or skin folds without specialist dermatological advice, as the enhanced absorption in these occlusive areas leads to rapid skin atrophy.

Infection and Pregnancy

Betnovate should never be applied to skin that is infected, as this can mask signs of infection and allow it to spread and worsen. Bacterial, fungal, and viral skin infections must be treated with appropriate antimicrobial therapy before or alongside any corticosteroid treatment; combination products containing betamethasone with an antibiotic or antifungal (such as Fucibet or Lotriderm) may be appropriate for infected inflammatory skin conditions.

During pregnancy, Betnovate should be used with caution, in the smallest quantity and for the shortest duration needed. Extensive application during pregnancy has been associated with reduced foetal birth weight and adrenal suppression. It should be used only if the benefit to the mother clearly outweighs any potential risk to the foetus.

Betnovate must not be used in the following circumstances:

• Untreated bacterial, fungal, or viral skin infections at the application site
• Rosacea and perioral dermatitis (potent steroids worsen both conditions significantly)
• Acne vulgaris
• Pruritus without diagnosis -- the underlying cause must be established before treatment
• Perianal and genital pruritus
• Nappy rash in infants (potent steroids must not be used for this indication)
• Known hypersensitivity to betamethasone valerate or any ingredient in the formulation
• Application around the eyes or on the eyelids (risk of glaucoma and cataracts)
• Widespread psoriasis requiring extensive application (risk of systemic absorption and rebound)